Cargando…
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study
BACKGROUND: Mesothelioma is an aggressive thoracic tumour with a poor prognosis. The only treatment that extends survival is chemotherapy. However, in the UK, up to 50% of patients who are suitable for chemotherapy choose not to receive it, opting for active symptom control instead. The aim of this...
Autores principales: | Bibby, Anna C., De Fonseka, Duneesha, Morley, Anna J., Keenan, Emma, Addeo, Alfredo, Smith, Sarah, Edey, Anthony J., Maskell, Nick A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723074/ https://www.ncbi.nlm.nih.gov/pubmed/29221485 http://dx.doi.org/10.1186/s12904-017-0255-3 |
Ejemplares similares
-
Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma
por: De Fonseka, Duneesha, et al.
Publicado: (2022) -
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
por: de Fonseka, Duneesha, et al.
Publicado: (2018) -
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
por: de Fonseka, Duneesha, et al.
Publicado: (2018) -
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
por: Arnold, David T, et al.
Publicado: (2017) -
Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)
por: de Fonseka, Duneesha, et al.
Publicado: (2018)